Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending

Phase 3positivePositive

AI Analysis

Summary

Hengrui Pharma and Kailera Therapeutics' investigational oral GLP-1 achieved positive late-stage results in China, clearing the path for regulatory submission, though ongoing US studies face potential challenges from elevated nausea and vomiting rates.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

cleared late-stage bar in China; high rates of nausea and vomiting noted as potential challenge for US study

Importance:7/10

Sentiment:

0.60

GLP-1oral formulationweight lossChina regulatoryUS trial pendingsafety concerns

Related Companies

$KLRA

Read the original article

Published by BioSpace on July 7, 2026 3:44 PM

Read Original